Condition
Infections, Coronavirus
Total Trials
5
Recruiting
0
Active
0
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
33%
1 of 3 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
2Total
P 2 (2)
Trial Status
Completed3
Unknown2
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT04381377Phase 2CompletedPrimary
Efficacy and Safety of Polyoxidonium® in Hospitalized Patients With Coronavirus Disease COVID-19
NCT04319172Completed
Multicentric Study of Coronavirus Disease 2019 (COVID-2019) in Solid Organ Transplant Recipients
NCT04542226CompletedPrimary
Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19
NCT04511429UnknownPrimary
COVID-19 in Immunosuppressed Children
NCT04385186Phase 2UnknownPrimary
Inactivated Convalescent Plasma as a Therapeutic Alternative in Patients CoViD-19
Showing all 5 trials